This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Stevens-Johnson syndrome | |
|---|---|
| Name | Stevens-Johnson syndrome |
| Field | Dermatology, Immunology, Allergy |
Stevens-Johnson syndrome is a rare, severe mucocutaneous reaction characterized by epidermal necrosis and detachment affecting skin and mucous membranes. It presents acutely with painful lesions, systemic symptoms, and risk of life-threatening complications, and requires multidisciplinary care across dermatology, ophthalmology, and critical care. Historical case series, pharmacovigilance reports, and immunopathology studies have shaped current diagnostic criteria and management protocols in hospitals and specialty centers.
Initial presentation often includes prodromal fever and systemic malaise leading to targetoid skin lesions, widespread erythema, and epidermal sloughing. Prominent mucosal involvement affects the oral cavity, conjunctivae, and genitalia with erosions and hemorrhagic crusting, and may progress to respiratory and gastrointestinal mucosal injury. Cutaneous findings can mimic toxic epidermal necrolysis and are assessed for body surface area involvement, Nikolsky's sign, and secondary infection risk in burn units and intensive care settings. Ocular sequelae such as symblepharon, corneal ulceration, and vision loss require urgent ophthalmology evaluation and can overlap with complications seen after chemical injuries treated in trauma centers.
Most cases are idiosyncratic reactions to medications, with strong associations reported for sulfonamides, antiepileptics, allopurinol, and certain nonsteroidal anti-inflammatory drugs; infectious triggers such as Mycoplasma pneumoniae and herpesviridae are also documented. Genetic predisposition involving HLA alleles and pharmacogenomic markers has been identified in population studies and pharmacovigilance databases, informing screening programs in communities and regulatory guidance. Pathophysiology involves a cytotoxic T‑cell–mediated process, keratinocyte apoptosis, and immune complex formation with cascade activation similar to mechanisms studied in graft rejection and autoimmune blistering diseases. Immunopathology parallels concepts explored in transplantation immunology, rheumatology research, and vaccine safety assessments in public health literature.
Diagnosis is clinical, supported by dermatopathology from skin biopsy showing full‑thickness epidermal necrosis and sparse dermal inflammation; immunofluorescence and microbiology help exclude bullous pemphigoid, pemphigus vulgaris, and staphylococcal scalded skin syndrome. Scoring systems and severity indices used in tertiary centers and burn units guide prognosis estimation, triage, and resource allocation. Laboratory evaluation includes tests for electrolyte disturbances, hepatic and renal function commonly monitored in nephrology and hepatology services, and screening for implicated infectious agents by microbiology laboratories affiliated with academic hospitals.
Immediate withdrawal of suspected causative agents and supportive care in specialized units or burn centers constitute the cornerstone of management, with fluid and electrolyte replacement, wound care, pain control, and nutritional support. Adjunctive immunomodulatory therapies—such as corticosteroids, intravenous immunoglobulin, cyclosporine, and tumor necrosis factor inhibitors—have been evaluated in clinical trials and meta-analyses reported by academic medical centers, though consensus varies among guidelines promulgated by professional societies. Ophthalmology intervention, including topical therapy and surgical procedures, is critical to preserve vision, while respiratory support and airway management align with practices in anesthesiology and critical care medicine.
Mortality correlates with extent of epidermal detachment, comorbidities, and age, with long‑term morbidity including scarring, pigmentary changes, ocular surface disease, and chronic mucosal dysfunction. Survivors may require rehabilitation, reconstructive surgery, and long‑term follow‑up with dermatology, ophthalmology, and physical medicine specialists affiliated with academic institutions. Public health registries, transplant centers, and pharmacovigilance networks track outcomes, and health economics analyses assess the burden on tertiary care systems and insurance payers.
Incidence estimates vary by region, with higher rates reported in pharmacogenetically susceptible populations and in association with prescribing patterns in primary care, neurology, and rheumatology practices. Population studies, adverse event reporting systems, and case series from referral centers provide data on age distribution, drug associations, and geographic variability noted in international surveillance reports and global health summaries. Seasonal and outbreak patterns linked to infectious triggers have been described in epidemiologic investigations conducted by public health agencies and academic research institutions.
Prevention emphasizes pharmacovigilance, prescriber education, and pharmacogenetic screening programs implemented in healthcare systems, with formularies and regulatory advisories guiding high‑risk drug avoidance in susceptible individuals. Early recognition protocols, emergency department algorithms, and referral pathways to burn units and specialty clinics are promoted by professional societies and emergency medicine networks. Patient registries, counseling by genetic services, and coordination among primary care, specialty clinics, and public health departments support risk mitigation, secondary prevention, and preparedness planning for severe adverse drug reactions.
Category:Cutaneous conditions